BerGenBio will present translational work from its BGBC004 trial of BGB324 in patients with stage IIIb or stage IV Non-Small Cell Lung Cancer.
Meet BerGenBio scientists and the study’s lead PI presenting their poster entitled:
A Phase I/II and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced Non-Small Cell Lung Cancer (NSCLC)
Date: 29 November 2016
Time: 11:45am – 6.30pm
Poster Session: Molecular targeted agents I
Poster board number: P007
More details can be viewed here.